

31/10/2019

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Dear Sir,

Sub: Outcome of the Board Meeting under Regulation 30 and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.


BSE Code: 531210

We would like to inform you that, the Board of Directors of the Company at their meeting held today i.e. 31st October, 2019 has, inter alia considered and approved Unaudited Financial Results (as per IND-AS) for the quarter and half year ended on 30th September, 2019.

Enclosed herewith a copy of the same along with a copy of Limited Review Report dated 31-10-2019 received from Vora & Associates, Chartered Accountants, Statutory Auditors of the Company with respect to Unaudited Financial Results for the quarter and half year ended on 30th September, 2019, along with Cash-Flow statement.

The chairman with consent of other Directors present, placed before the board the mail/notice received from Bombay Stock Exchange, Mumbai, dated 15-10-2019 (LIST/COMP/531210/REG.34-Mar19/206/2018-19). As per the above mail/notice received, it is informed to the company that a fine of Rs. 72,000/- +GST @18%, 12960/- total 84,960/- is imposed on the company, since, the Company has not submitted the Annual Report for the financial year ended 31-03-2019 within the stipulated time specified in the amended SEBI(LODR) Reg. 34 (vide SEBI circular no SEBI/HO/CFD/CMD/CIR/P/2018/77) dated 03-05-2018.

The entire board expressed surprise and shock in this matter, since the company was aware about the circular and action of sending the Annual Report to the shareholders and as well as to BSE at the same time. The Company had accordingly, complied with the requirement of sending the Annual Report to BSE at the same time, when the Annual Report was sent to the Shareholders.



The Chairman placed before the board the following;

- a) The mail/notice received from the BSE.
- b) The reply sent by the company along with the proof of dispatch. The elaborate reply sent by the company to BSE is self-explanatory

Thereafter the Directors individually pursued the mail/notice of the BSE and the reply sent by Dr. Mani (Director and Company Secretary) to BSE informing them the fact of the matter in this case.

In view of the above the Board of Directors expressed their satisfaction with the matter and noted that there was no question of non-compliance with regard to the amended LODR Reg. 33 as per the circular referred to the above by BSE. The Board of Directors of the Company also expressed the hope that the BSE/SEBI will waive of the fine imposed, since the company has complied with the requirements specified.

The Meeting commenced at 1.30 PM and concluded at 6.00 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD

DR. MANI L.S.

Director- Legal, Company Secretary & Compliance Officer

DIN: 00825886





VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

022-2200 5933 - 2200 5934
022-2206 3289 - 6615 5599

www.cavoras.com
office@cavoras.com
cavoras@gmail.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.


We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the quarter and half year ended 30th September, 2019 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).


This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)


RONAK A. RAMBHIA
PARTNER
(Membership No.: 140371)



UDIN: 19140371AAAACZ8281
PLACE: MUMBAI
DATED: 31 OCT 2019

COLINZ LABORATORIES LIMITED.

(CIN NO: L24200MH1986PLC041128)

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED "" 30TH SEPTEMBER-2019""

""(Rupees in Lakhs)""

S. No.	PARTICULARS	UN-AUDITED					AUDITED
		QUARTER ENDED			SIX MONTH ENDED		YEAR ENDED
		30-Sep-2019	30-Jun-2019	30-Sep-2018	30-Sep-2018	30-Sep-2019	31-Mar-2019
PART-I							
1	(a)Revenue from Operation	199.30	202.47	199.60	408.10	401.77	766.82
2	(b) Other Income	2.99	2.86	3.08	5.84	5.85	11.84
3	Total Revenue from Operation (a+b)	202.29	205.33	202.68	413.94	407.62	778.66
4	Expenses						
	a Cost Of Material Consumed	28.79	22.08	14.73	57.66	50.87	93.34
	b Purchase of Stock in Trade	37.64	45.90	53.84	97.80	83.54	179.43
	c) Change in Inventories Of Finished Goods and Work in Progress of Stock in trade.	11.69	4.80	5.72	(6.83)	16.49	7.69
	d Employee Benefit Expenses	87.07	86.41	89.70	178.61	173.48	336.66
	e Finance Cost	1.30	2.86	2.58	4.71	4.16	9.74
	f) Depreciation & Amortisation Expenses	4.84	4.84	5.39	10.78	9.68	21.59
	g Other Expenses	25.92	31.97	24.73	60.71	57.89	114.64
	Total Expenses	197.25	198.86	196.69	403.42	396.11	763.09
5	Profit /(Loss) Before exceptional items and tax (5.04	6.47	5.99	10.51	11.51	15.57
6	Exceptional items						
7	Profit /(Loss) before tax (5-6)	5.04	6.47	5.99	10.51	11.51	15.57
8	Tax Expenses (Provision for Taxation) Current tax						
	i) Current Tax	0.75	1.25	0.50	1.50	2.00	6.99
	ii) Tax for earlier years	-	-	-	-	-	(3.16)
	iii) MAT Credit of Earlier years	-	-	-	-	-	-
	iv) Deferred Tax	-	-	-	-	-	(0.43)
9	Profit /(Loss) for the period from continuing	4.29	5.22	5.49	9.01	9.51	12.17
10	Profit /(Loss) from discontinued operations	-	-	-			
11	Tax expenses of discontinued operations	-	-	-			
12	Profit /(Loss) for the period (9+10-11)	4.29	5.22	5.49	9.01	9.51	12.17
13	Other Comprehensive Income (NET OF TAX)						
	A) i) Item that will not be reclassified to Profit or	(2.05)	(1.29)	(6.65)	(4.78)	(3.35)	(3.01)
	ii) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
14	Total Comprehensive Income for the period (12+13) Comprising Profit /(Loss) and Other	2.24	3.93	(1.16)	4.24	6.16	9.16
15	Earning per equity share (for Continuing						
	i) Basic	0.05	0.09	(0.03)	0.090	0.13	0.20
	ii Diluted						



Colinz Laboratories Limited


CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

STATEMENT OF ASSETS AND LIABILITIES					
Particulars				30-Sep-2019	31-Mar-2019
Non-Current Assets					
a) Property, Plants & Equipment				211.33	221.00
b) Capital Work-in progress				-	-
c) Intangible Assets				-	-
d) Financial Assets					
i) Investments				46.32	49.67
ii) Loans				-	-
iii) Other Financial Assets				-	-
e) Other Non Current Assets				74.57	82.75
Total Non-Current Assets				332.22	353.42
Current Assets					
a) Inventories				171.64	189.85
b) Financial Assets					
i) Trade Receivables				174.58	167.77
ii) Cash & Cash Equivalents				29.54	27.51
iii) Other Bank Balances				176.61	171.78
iv) Other Financial Assets				-	-
c) Other Current Assets				6.75	7.16
Total Current Assets				559.12	564.07
TOTAL ASSETS				891.34	917.49
EQUITY AND LIABILITIES					
Equity					
a) Equity Share Capital				354.41	354.41
b) Other Equity				336.00	329.84
Total Equity				690.41	684.25
Liabilities					
Non-Current Liabilities					
a) Deferred Tax Liabilities (Net)				28.93	28.93
b) Other Non Current Liabilities				25.69	25.69
Total Non-Current Liabilities				54.62	54.62
Current Liabilities					
a) Financial Liabilities					
i) Borrowings				29.66	67.54
ii) Trade Payables				39.25	34.28
b) Other Current Liabilities				65.48	64.87
c) Current Provisions				11.92	11.93
Total Current Liabilities				146.31	178.62
TOTAL EQUITY AND LIABILITIES				891.34	917.49



Colinz Laboratories Limited
CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006

COLINZ LABORATORIES LTD.

CASH FLOW STATEMENT FOR THE YEAR ENDED 30-09-2019

All amounts in Rupees, unless otherwise stated

A) CASH FLOW FROM OPERATING ACTIVITIES:

Profit Before Taxation

Adjustments for:

Depreciation/Impairment

Interest Expense

Interest Income

Dividend Income

Operating Profit Before Working Capital ChangesAdjustments for changes in working capital:

Increase / (Decrease) in Trade Payable

Increase / (Decrease) in Short Term Borrowings

Increase / (Decrease) in Current Provisions

Increase / (Decrease) in Other Current Liabilities

Increase / (Decrease) in Other Long Term Current Liabilities

(Increase) / Decrease in Trade Receivables

(Increase) / Decrease in Inventories

(Increase) / Decrease in Other Non Current Assets

(Increase) / Decrease in Other Current Assets

Cash Generated / (Used In) from Operations

Taxes Paid (Net)

Net Cash generated from / (Used In) Operating Activities**B) CASH FLOW FROM INVESTING ACTIVITIES:**

Purchase of Fixed Assets

Investments in shares & securities (Net)

Dividend Income

Net Cash (Used In) Investing Activities**C) CASH FLOW FROM FINANCING ACTIVITIES:**

Interest received

Interest Expense

Net Cash (Used In) / generated from Financing Activities**Net increase in Cash and Cash Equivalents (A+B+C)**

Cash and Cash Equivalents as at the beginning of the year

Cash and Cash Equivalents as at the end of the year

Cash and Cash Equivalents comprise of:

Cash in Hand

Balances with Scheduled Banks in:


- Current Accounts

Other Bank Balances

01-04-19 To 30-09-19	01-04-18 To 30-09-18
1,150,703	1,051,498
967,471	1,077,674
416,351	470,502
(559,422)	(557,240)
(25,421)	(26,362)
1,949,681	2,016,072
496,214	(571,934)
(3,788,912)	3,647,712
-	(173,022)
60,940	(1,966,995)
-	-
(681,430)	(4,405,977)
1,821,101	(408,198)
818,591	1,758,011
41,236	(310,446)
717,421	(414,777)
(200,000)	(150,000)
517,421	(564,777)
-	-
-	-
25,421	26,362
25,421	26,362
559,422	557,240
(416,351)	(470,502)
143,071	86,738
685,913	(451,676)
19,929,429	18,699,706
20,615,341	18,248,029
685,913	(451,676)
349,729	347,769
2,604,365	1,255,402
17,661,247	16,644,858
20,615,341	18,248,029

Notes:

1. The above cash flow statement has been prepared under the "Indirect Method" set out in Ind AS on "Statement of Cash Flow" issued by the Institute of Chartered Accountants of India.




NOTES TO THE FINANCIAL RESULTS :-

- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 31st Oct, 2019.
- 2) The above results of the Company has been reviewed by the Statutory Auditors and they have issued a Limited Review Report on the same.
- 3) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 4) Previous figures have been regrouped/ rearranged , wherever necessary.
- 5) This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

MUMBAI.
31st Oct, 2019

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128


Dr. MANI L.S.
(Director-Legal, Corporate Affairs & Company Secretary)
(DIN NO : 00825886)



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006